Tricyclic antidepressants, particularly amitriptyline and nortriptyline, are the strongest oral medications for nerve pain based on clinical trial data. They have the lowest “number needed to treat” of any drug class, meaning fewer people need to take them before one person gets significant relief. But “strongest” doesn’t always mean “best for you,” because side effects, your specific condition, and how well you tolerate a drug all factor into what actually works.
How Drug Strength Is Measured for Nerve Pain
Researchers compare nerve pain drugs using a metric called the number needed to treat, or NNT. It tells you how many people need to take a drug before one person gets at least 50% pain reduction. A lower number means the drug works for a higher percentage of people. An NNT of 2 means one out of every two people gets meaningful relief. An NNT of 5 means only one in five does.
This matters because nerve pain drugs don’t work the same way as, say, ibuprofen for a headache. No single nerve pain medication reliably eliminates pain for everyone. The goal is usually a 30 to 50% reduction in pain intensity, which sounds modest but can be the difference between being unable to sleep and functioning normally.
Tricyclic Antidepressants: The Strongest by the Numbers
Tricyclic antidepressants consistently show the lowest NNT values across nerve pain conditions. For postherpetic neuralgia (the lingering pain after shingles), tricyclics have an NNT around 2.1 to 2.3. For diabetic neuropathy, the NNT ranges from 2.4 to 3.4. That means roughly one in every two to three people taking these drugs gets at least 50% pain relief.
In a head-to-head trial comparing amitriptyline and duloxetine for painful diabetic neuropathy, 55% of patients on amitriptyline achieved good pain relief, while 59% on duloxetine did. Overall, about 62% of amitriptyline patients and 64% of duloxetine patients saw at least a 30% improvement. The two drugs performed almost identically, but tricyclics have a longer track record and cost less.
The catch is side effects. Tricyclics cause dry mouth, drowsiness, weight gain, constipation, and dizziness more often than newer options. They can also affect heart rhythm, which makes them a poor fit for people with certain cardiac conditions. This is why guidelines list them as first-line but not necessarily the default starting point for every patient.
Gabapentin and Pregabalin: The Most Commonly Prescribed
Gabapentin and pregabalin work by reducing calcium signaling in overactive nerve cells, which dials down the release of chemical messengers that amplify pain signals in the spinal cord. They’re among the most widely prescribed nerve pain drugs because they’re effective and generally better tolerated than tricyclics.
Gabapentin’s NNT ranges from 3.2 to 5.1 depending on the condition. Pregabalin’s NNT is about 3.4 for postherpetic neuralgia and 4.2 for diabetic neuropathy. These numbers are slightly higher (meaning slightly less effective on a population level) than tricyclics, but the gap isn’t enormous.
Pregabalin has a practical advantage over gabapentin: it’s absorbed more predictably and works faster. In clinical comparisons, pregabalin showed significantly better pain reduction than gabapentin by four weeks of treatment, though at two weeks the drugs performed similarly. Pregabalin also kicks in more quickly during acute pain flares. Typical therapeutic doses run up to 300 mg per day for pregabalin and up to 1,800 mg per day for gabapentin, though doses can go higher. Both cause drowsiness and dizziness as common side effects, and pregabalin carries some risk of misuse, which has led France to downgrade it to a second-line option.
Duloxetine and Venlafaxine: The SNRI Option
Duloxetine and venlafaxine belong to a class of antidepressants that boost two brain chemicals involved in the body’s natural pain-suppression pathways: serotonin and norepinephrine. They don’t work through the same mechanism as tricyclics, but the end result is similar. Duloxetine’s NNT for postherpetic neuralgia is 4.1 to 5.0, putting it in the same range as gabapentin but behind tricyclics.
Duloxetine tends to cause fewer side effects than amitriptyline, particularly less sedation and fewer heart-related concerns. Nausea is the most common complaint early on, but it usually fades. For people who can’t tolerate tricyclics or gabapentinoids, duloxetine is a strong alternative. International pain guidelines from the International Association for the Study of Pain list it alongside gabapentin and tricyclics as a primary treatment option.
Why Combining Two Drugs Often Works Better
One of the most useful findings in nerve pain research is that combining drugs from different classes can outperform either drug alone. In a well-designed crossover trial, patients started with average pain scores of 5.4 out of 10. On gabapentin alone, pain dropped to 3.2. On nortriptyline (a tricyclic) alone, it dropped to 2.9. But on both drugs together, pain fell to 2.3, a statistically significant improvement over either drug by itself.
This is particularly relevant if you’ve tried one medication and gotten partial but not adequate relief. Rather than switching to something entirely new, adding a second drug that works through a different mechanism can close the gap. Guidelines now formally recommend combination therapy as a second-line approach for this reason.
Where Opioids Fit In
Strong opioids are technically potent painkillers, but they perform surprisingly poorly for nerve pain specifically. Guidelines place them firmly in the third line, reserved for cases where nothing else has worked. Their effectiveness for neuropathic conditions is low relative to the risks of dependence, tolerance, and side effects.
Tramadol, a weaker opioid, sits slightly higher as a second-line option. Tapentadol, a newer opioid designed to also target norepinephrine pathways, was initially marketed as a better option for nerve pain, but the evidence has been disappointing. Only two of three trials in diabetic neuropathy showed it was better than placebo, and its efficacy was considered inferior to tramadol’s. Clinical reviewers have concluded it does not offer a meaningful improvement over existing treatments.
Topical Treatments for Localized Pain
If your nerve pain is concentrated in a specific area, topical options can deliver strong relief without the systemic side effects of oral medications. Lidocaine patches are a first-line option for focal peripheral nerve pain. High-concentration capsaicin patches (8%) are a second-line option that works by overwhelming and then desensitizing the nerve endings in the skin.
A single 30 to 60 minute application of the capsaicin patch can reduce pain for about three months, with a median time between treatments of 125 days. In clinical practice, about 70% of patients experienced at least a 30% reduction in pain scores. For postherpetic neuralgia specifically, two-thirds of patients responded. The application itself can cause a temporary burning sensation, but once that passes, the relief is sustained without daily medication.
How Treatment Typically Progresses
Current guidelines organize nerve pain treatment into tiers. First-line options include tricyclic antidepressants, gabapentin, pregabalin, and duloxetine or venlafaxine, with topical lidocaine for localized pain. If a first-line drug provides partial relief, combining it with a drug from a different class is the next step. Tramadol, capsaicin patches, and certain non-drug therapies like transcutaneous electrical nerve stimulation sit in the second tier.
Strong opioids and more invasive approaches like spinal cord stimulation are reserved for people who haven’t responded to anything else. Most people find adequate relief within the first two tiers, especially with combination therapy. The process of finding the right drug or combination typically takes weeks to months, because most nerve pain medications need two to four weeks at a therapeutic dose before you can fairly judge whether they’re working.